This Article Full Text Full Text (PDF) Erratum (v22,p1534) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rivera, E. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Rivera, E. Articles by Hortobagyi, G. N. Social Bookmarking                            What's this?

Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer

From the Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Edgardo Rivera, MD, Department of Breast Medical Oncology, Box 424, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009; email: erivera{at}notes.mdacc.tmc.edu

PURPOSE: We conducted a single-institution phase I clinical trial to determine the maximum-tolerated dose (MTD) and define the toxic effects of stealth liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.

PATIENTS AND METHODS: Patients were eligible if they had disease progression with no limit on prior number of chemotherapy regimens. Prior treatment with liposomal doxorubicin and/or gemcitabine was not allowed. The starting dose of liposomal doxorubicin was 20 mg/m² on day 1 only with a 20% dose escalation of the previous mg/m² dose until MTD was reached. Gemcitabine was given as a fixed dose of 800 mg/m² on days 1 and 8 every 3 weeks.

RESULTS: We treated 27 patients of whom six had never received chemotherapy for their disease. Most had had visceral involvement as their dominant site of disease. The dose-limiting toxicity was myelosuppression, which included neutropenia and thrombocytopenia. However, neither neutropenic fever nor episodes of bleeding were major occurrences. Significant antitumor activity was also observed with a total of two complete and seven partial responses. The recommended phase II dose is liposomal doxorubicin 24 mg/m² on day 1 and gemcitabine 800 mg/m² on days 1 and 8 every 21 days.

CONCLUSION: The combination of liposomal doxorubicin and gemcitabine is an active and well tolerated regimen when administered on a 21-day schedule. Myelosuppression limited further dose escalation, however, it did not increase the incidence of neutropenic fever. Significant antitumor activity seen in heavily and minimally pretreated patients warrants further evaluation of this combination.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Rivera, V. Valero, B. Arun, M. Royce, R. Adinin, K. Hoelzer, R. Walters, J. L. Wade III, L. Pusztai, and G. N. Hortobagyi Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3249 - 3254. [Abstract] [Full Text] [PDF]

				E. Rivera Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update Oncologist, August 1, 2003; 8(90002): 3 - 9. [Abstract] [Full Text] [PDF]